1 active not recruiting, 1 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Plasma Cell Myeloma Refractory: new trials by email Literature Review of Plasma Cell Myeloma Refractory trials Research Report on Plasma Cell Myeloma Refractory
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma Isatuximab SC-OBDS, Montelukast, Dexamethasone - Plasma Cell Myeloma Refractory | Phase 2 | Active not recruiting | Sanofi | 64 | 2025-03-17 | 2026-10-26 |
| Isatuximab in Combination With Novel Agents in RRMM - Master Protocol Isatuximab, Dexamethasone, Pomalidomide - Plasma Cell Myeloma Refractory | Phase 1 / Phase 2 | Recruiting | Sanofi | 258 | 2021-01-25 | 2026-10-13 |
Dexamethasone (2) · isatuximab (2) · ALX148 (1) · Acetaminophen (1) · Diphenhydramine (1) · Methylprednisolone (1) · belantamab mafodotin (1) · belumosudil (1) · carfilzomib (1) · montelukast (1) · pomalidomide (1)
Sanofi (2)
United States (2) · Australia (1) · France (1) · Germany (1) · Greece (1) · Israel (1) · Italy (1) · Norway (1) · South Korea (1)